Medical Condition News

RSS

Research must focus on discovering potential causes and treatments for Bell's palsy

Drugs widely prescribed to treat facial paralysis in Bell's palsy are ineffective and are based on false notions of the cause of the condition, according to Cochrane Researchers. They say research must now focus on discovering other potential causes and treatments.

7 Oct 2009

HRT may increase urinary incontinence in postmenopausal women

Grappling with the risks and benefits of hormone replacement therapy (HRT) is nothing new for postmenopausal women. Researchers have now added more fuel to the fire, with evidence that HRT could play a role in incontinence.

7 Oct 2009

Scientists create new technology to improve detection of leukemia cells in bone marrow

Scientists have created a viable technology to improve the detection of leukemia cells in bone marrow.

7 Oct 2009

Jobless individuals are four times as likely as employed to report depression

A new national survey shows the economic downturn is taking a toll on the mental health of Americans. Individuals who are unemployed are four times as likely as those with jobs to report symptoms consistent with severe mental illness.

7 Oct 2009

Low levels of ROS might protect us from diabetes, says study

We've all heard about the damage that reactive oxygen species (ROS) - aka free radicals - can do to our bodies and the sales pitches for antioxidant vitamins, skin creams or "superfoods" that can stop them. In fact, there is considerable scientific evidence that chronic ROS production within cells can contribute to human diseases, including insulin resistance and type 2 diabetes.

7 Oct 2009

New findings on Alzheimer's disease suggest a possible way for treatment

The action of a small protein that is a major villain in Alzheimer's disease can be counterbalanced with another brain protein, researchers at UT Southwestern Medical Center have found in an animal study.

7 Oct 2009

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Data results published this month in Clinical Neuropharmacology, revealed that Merz Pharmaceuticals' NT 201 (botulinum toxin type A free from complexing proteins), also known by the brand name Xeomin in Europe and Canada, was statistically significantly more efficacious than placebo for the treatment of patients with post-stroke upper limb spasticity.

7 Oct 2009

B-vitamin supplements do not prevent heart attack

B-vitamin supplements should not be recommended for prevention of heart disease, say scientists. A Cochrane Systematic Review has shown these supplements do not reduce the risk of developing or dying from the disease.

7 Oct 2009

More research required to determine efficacy of Chinese herbal medicines in preventing diabetes

More research is required to establish whether Chinese herbal medicines can reduce the likelihood of developing diabetes, according to Cochrane Researchers. Although herbal medicines are widely used in Asian countries to treat pre-diabetes (impaired glucose tolerance or IGT), the precursor of the disease, researchers say there is still not enough hard scientific evidence to confidently recommend their use.

7 Oct 2009

Aerobic and strength training exercises safe and effective for rheumatoid arthritis patients

Exercise programs designed to improve strength and stamina are safe and effective treatments for rheumatoid arthritis (RA), according to a new Cochrane Systematic Review.

7 Oct 2009

Cardiorespiratory training can improve walking in stroke patients

An updated Cochrane review finds that stroke patients who participate in a post-stroke walking program walk faster, longer and more independently than non-exercisers.

7 Oct 2009

Primary care providers should screen all adults for depression: ACPM

The American College of Preventive Medicine (ACPM) supports the recommendations of the US Preventive Services Task Force (USPSTF) that primary care providers should screen all adults for depression, and further recommends that all primary care providers should have systems in place to ensure the accurate diagnosis and treatment of this condition.

7 Oct 2009

Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis

Biovail Corporation today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with ACADIA Pharmaceuticals Inc. Following the announcement on September 1st of disappointing top-line results from the first Phase III PDP trial, Biovail and ACADIA remain committed to the successful development of pimavanserin and have established a development strategy that they believe will strengthen the PDP program.

7 Oct 2009

$16 million federal stimulus funds establish Seattle as national hub for cancer research

Researchers at Fred Hutchinson Cancer Research Center, Group Health Research Institute and the University of Washington schools of Public Health and Pharmacy have been selected to lead four projects backed by approximately $16 million in federal stimulus funding for comparative-effectiveness research in cancer.

7 Oct 2009

Cognitive behavioral therapy effective for bulimia and binge eating disorders

Although most people with bulimia and binge eating disorders wait many years before seeking help, a new review shows that psychological treatment can make a large difference — and that cognitive behavioral therapy (CBT) is the most effective talk therapy for these disorders.

6 Oct 2009

FDA provides 510(k) clearance for Boston Scientific's WallFlex Biliary RX covered stents

Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its WallFlex(®) Biliary RX fully and partially covered stents for the palliative treatment of malignant bile duct strictures. The WallFlex Biliary RX uncovered stent was cleared by the FDA in 2006.

6 Oct 2009

US Army grants BioDelivery Sciences $1.3M for investigating Bioral Amphotericin B

BioDelivery Sciences International, Inc. has received a $1.3 million grant from the Walter Reed Army Institute of Research for Bioral Amphotericin B, an oral formulation of the fungicidal treatment amphotericin B in BDSI’s patented Bioral drug delivery technology, to further study the formulation in the treatment of Cutaneous Leishmaniasis.

6 Oct 2009

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

AVANIR Pharmaceuticals, Inc. today announced it will present detailed data from the Phase III confirmatory STAR trial in the treatment of pseudobulbar affect (PBA) at the 3rd World Congress on Controversies in Neurology (CONy) in Prague, Czech Republic on October 8 - 11, 2009 and the American Neurological Association (ANA) 134th Annual Meeting in Baltimore, MD on October 11 - 14, 2009.

6 Oct 2009

pDCs promote growth and survival of malignant myeloma cells

Multiple myeloma cancer cells thwart many of the drugs used against them by causing nearby cells to turn traitor - to switch from defending the body against disease to shielding the myeloma cells from harm - Dana-Farber Cancer Institute scientists report in the October issue of Cancer Cell.

6 Oct 2009

iMedicor to market Access Pharmaceuticals' MuGard in North America

ACCESS PHARMACEUTICALS, INC. announced today that it had signed an agreement with iMedicor for the North American commercial launch of MuGard, its FDA approved mucoadhesive oral rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy.

6 Oct 2009

Medical Condition News

Research must focus on discovering potential causes and treatments for Bell's palsy

HRT may increase urinary incontinence in postmenopausal women

Scientists create new technology to improve detection of leukemia cells in bone marrow

Jobless individuals are four times as likely as employed to report depression

Low levels of ROS might protect us from diabetes, says study

New findings on Alzheimer's disease suggest a possible way for treatment

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

B-vitamin supplements do not prevent heart attack

More research required to determine efficacy of Chinese herbal medicines in preventing diabetes

Aerobic and strength training exercises safe and effective for rheumatoid arthritis patients

Cardiorespiratory training can improve walking in stroke patients

Primary care providers should screen all adults for depression: ACPM

Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis

$16 million federal stimulus funds establish Seattle as national hub for cancer research

Cognitive behavioral therapy effective for bulimia and binge eating disorders

FDA provides 510(k) clearance for Boston Scientific's WallFlex Biliary RX covered stents

US Army grants BioDelivery Sciences $1.3M for investigating Bioral Amphotericin B

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

pDCs promote growth and survival of malignant myeloma cells

iMedicor to market Access Pharmaceuticals' MuGard in North America

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News